Avalo Therapeutics, Inc. (AVTX)
14.42
+1.07
(+8.02%)
USD |
NASDAQ |
Apr 16, 16:00
14.32
-0.10
(-0.69%)
After-Hours: 20:00
Avalo Therapeutics Research and Development Expense (Quarterly) : 13.27M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Catalyst Pharmaceuticals, Inc. | 1.807M |
| AbbVie, Inc. | 2.579B |
| Relmada Therapeutics, Inc. | 8.072M |
| Theravance Biopharma, Inc. | 6.963M |
| Corcept Therapeutics, Inc. | 64.86M |